292 related articles for article (PubMed ID: 34775830)
21. Abrocitinib induction, randomized withdrawal, and retreatment in patients with moderate-to-severe atopic dermatitis: Results from the JAK1 Atopic Dermatitis Efficacy and Safety (JADE) REGIMEN phase 3 trial.
Blauvelt A; Silverberg JI; Lynde CW; Bieber T; Eisman S; Zdybski J; Gubelin W; Simpson EL; Valenzuela F; Criado PR; Lebwohl MG; Feeney C; Khan T; Biswas P; DiBonaventura M; Valdez H; Cameron MC; Rojo R
J Am Acad Dermatol; 2022 Jan; 86(1):104-112. PubMed ID: 34416294
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and Safety of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial.
Silverberg JI; Simpson EL; Thyssen JP; Gooderham M; Chan G; Feeney C; Biswas P; Valdez H; DiBonaventura M; Nduaka C; Rojo R
JAMA Dermatol; 2020 Aug; 156(8):863-873. PubMed ID: 32492087
[TBL] [Abstract][Full Text] [Related]
23. Predicting Abrocitinib Efficacy at Week 12 Based on Clinical Response at Week 4: A Post Hoc Analysis of Four Randomized Studies in Moderate-to-Severe Atopic Dermatitis.
Armstrong AW; Alexis AF; Blauvelt A; Silverberg JI; Feeney C; Levenberg M; Chan G; Zhang F; Fostvedt L
Dermatol Ther (Heidelb); 2024 Jun; ():. PubMed ID: 38896380
[TBL] [Abstract][Full Text] [Related]
24. Comparing binary efficacy outcomes for systemic immunomodulatory treatments for atopic dermatitis in a living systematic review and network meta-analysis.
Drucker AM; Lam M; Elsawi R; Prieto-Merino D; Malek R; Ellis AG; Yiu ZZN; Rochwerg B; Di Giorgio S; Arents BWM; Burton T; Spuls PI; Schmitt J; Flohr C
Br J Dermatol; 2024 Jan; 190(2):184-190. PubMed ID: 37831594
[TBL] [Abstract][Full Text] [Related]
25. Infections in Children Aged 6 Months to 5 Years Treated with Dupilumab in a Placebo-Controlled Clinical Trial of Moderate-to-Severe Atopic Dermatitis.
Paller AS; Siegfried EC; Cork MJ; Arkwright PD; Eichenfield LF; Ramien M; Khokhar FA; Chen Z; Zhang A; Cyr SL
Paediatr Drugs; 2024 Mar; 26(2):163-173. PubMed ID: 38267692
[TBL] [Abstract][Full Text] [Related]
26. Real-world Experience of Abrocitinib Treatment in Patients with Atopic Dermatitis and Hand Eczema: Up to 28-week Results from the BioDay Registry.
Kamphuis E; Boesjes CM; Loman L; Kamsteeg M; Haeck I; Van Lynden-van Nes AMT; Politiek K; Van der Gang LF; De Graaf M; De Bruin-Weller MS; Schuttelaar MLA
Acta Derm Venereol; 2024 Feb; 104():adv19454. PubMed ID: 38323500
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and safety of abrocitinib for the treatment of moderate-to-severe atopic dermatitis: a meta-analysis of randomized clinical trials.
Meher BR; Mohanty RR; Padhy BM
J Dermatolog Treat; 2022 Jun; 33(4):2335-2343. PubMed ID: 34315323
[TBL] [Abstract][Full Text] [Related]
28. Abrocitinib effect on patient-reported outcomes in patients with moderate-to-severe atopic dermatitis: Results from phase 3 studies, including the long-term extension JADE EXTEND study.
Reich K; Silverberg JI; Papp KA; Deleuran M; Katoh N; Strober B; Beck LA; de Bruin-Weller M; Werfel T; Zhang F; Biswas P; DiBonaventura MD; Chan G; Farooqui SA; Kerkmann U; Clibborn C
J Eur Acad Dermatol Venereol; 2023 Oct; 37(10):2047-2055. PubMed ID: 37319109
[TBL] [Abstract][Full Text] [Related]
29. An evaluation of abrocitinib for moderate-to-severe atopic dermatitis.
Labib A; Yosipovitch G
Expert Rev Clin Immunol; 2022 Nov; 18(11):1107-1118. PubMed ID: 36173402
[TBL] [Abstract][Full Text] [Related]
30. An observational study of abrocitinib in adults with moderate-to-severe atopic dermatitis after switching from dupilumab.
Tong Z; Zhang Y; Zhou K; Zou Y; Wu Z; Chen J; Zhuang Z; Zhao Y; Gong T; Ji C
J Am Acad Dermatol; 2023 Oct; 89(4):826-828. PubMed ID: 37307992
[No Abstract] [Full Text] [Related]
31. High threshold efficacy responses in moderate-to-severe atopic dermatitis are associated with additional quality of life benefits: pooled analyses of abrocitinib monotherapy studies in adults and adolescents.
Ständer S; Bhatia N; Gooderham MJ; Silverberg JI; Thyssen JP; Biswas P; DiBonaventura M; Romero W; Farooqui SA
J Eur Acad Dermatol Venereol; 2022 Aug; 36(8):1308-1317. PubMed ID: 35462428
[TBL] [Abstract][Full Text] [Related]
32. Comparative efficacy and safety of systemic therapies used in moderate-to-severe atopic dermatitis: a systematic literature review and network meta-analysis.
Silverberg JI; Thyssen JP; Fahrbach K; Mickle K; Cappelleri JC; Romero W; Cameron MC; Myers DE; Clibborn C; DiBonaventura M
J Eur Acad Dermatol Venereol; 2021 Sep; 35(9):1797-1810. PubMed ID: 33991374
[TBL] [Abstract][Full Text] [Related]
33. Patient-Reported Symptoms and Disease Impacts in Adults With Moderate-to-Severe Atopic Dermatitis: Results From a Phase 2b Study With Abrocitinib.
Simpson EL; Wollenberg A; Bissonnette R; Silverberg JI; Papacharalambous J; Zhu L; Zhang W; Beebe JS; Vincent M; Peeva E; Bushmakin AG; Cappelleri JC; Chen L; Sikirica V; Xenakis J
Dermatitis; 2021 Oct; 32(1S):S53-S61. PubMed ID: 33795561
[TBL] [Abstract][Full Text] [Related]
34. Abrocitinib monotherapy in Investigator's Global Assessment nonresponders: improvement in signs and symptoms of atopic dermatitis and quality of life.
Blauvelt A; Boguniewicz M; Brunner PM; Luna PC; Biswas P; DiBonaventura M; Farooqui SA; Rojo R; Cameron MC
J Dermatolog Treat; 2022 Aug; 33(5):2605-2613. PubMed ID: 35763326
[TBL] [Abstract][Full Text] [Related]
35. Abrocitinib: A New FDA-Approved Drug for Moderate-to-Severe Atopic Dermatitis.
Perche PO; Cook MK; Feldman SR
Ann Pharmacother; 2023 Jan; 57(1):86-98. PubMed ID: 35587593
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety of abrocitinib for the treatment of adolescents and adults with moderate-to-severe atopic dermatitis: update of a living systematic review and meta-analysis.
Zheng H; Chen Y; Xu Y; Deng X
Eur J Dermatol; 2023 Oct; 33(5):530-543. PubMed ID: 38297930
[TBL] [Abstract][Full Text] [Related]
37. Clinically Meaningful Responses to Dupilumab in Adolescents with Uncontrolled Moderate-to-Severe Atopic Dermatitis: Post-hoc Analyses from a Randomized Clinical Trial.
Paller AS; Bansal A; Simpson EL; Boguniewicz M; Blauvelt A; Siegfried EC; Guttman-Yassky E; Hultsch T; Chen Z; Mina-Osorio P; Lu Y; Rossi AB; He X; Kamal M; Graham NMH; Pirozzi G; Ruddy M; Eckert L; Gadkari A
Am J Clin Dermatol; 2020 Feb; 21(1):119-131. PubMed ID: 31823222
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and Safety of Multiple Dupilumab Dose Regimens After Initial Successful Treatment in Patients With Atopic Dermatitis: A Randomized Clinical Trial.
Worm M; Simpson EL; Thaçi D; Bissonnette R; Lacour JP; Beissert S; Kawashima M; Ferrándiz C; Smith CH; Beck LA; Chan KC; Chen Z; Akinlade B; Hultsch T; Staudinger H; Gadkari A; Eckert L; Davis JD; Rajadhyaksha M; Graham NMH; Pirozzi G; Stahl N; Yancopoulos GD; Ardeleanu M
JAMA Dermatol; 2020 Feb; 156(2):131-143. PubMed ID: 31876900
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and safety of abrocitinib monotherapy in adolescents and adults: a post hoc analysis of the phase 3 JAK1 atopic dermatitis efficacy and safety (JADE) REGIMEN clinical trial.
Flohr C; Cork MJ; Ardern-Jones MR; Eichenfield LF; Barbarot S; Feeney C; Rojo R; Lazariciu I; Nesnas J
J Dermatolog Treat; 2023 Dec; 34(1):2200866. PubMed ID: 37036183
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and Safety of Dupilumab in Adolescents With Uncontrolled Moderate to Severe Atopic Dermatitis: A Phase 3 Randomized Clinical Trial.
Simpson EL; Paller AS; Siegfried EC; Boguniewicz M; Sher L; Gooderham MJ; Beck LA; Guttman-Yassky E; Pariser D; Blauvelt A; Weisman J; Lockshin B; Hultsch T; Zhang Q; Kamal MA; Davis JD; Akinlade B; Staudinger H; Hamilton JD; Graham NMH; Pirozzi G; Gadkari A; Eckert L; Stahl N; Yancopoulos GD; Ruddy M; Bansal A
JAMA Dermatol; 2020 Jan; 156(1):44-56. PubMed ID: 31693077
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]